Peer Review Report For: Potential business model for a European vaccine R&D infrastructure and its estimated socio-economic impact [version 1; peer review: 1 approved, 3 approved with reservations]
Year: 2023
Type: peer-review
Abstract: Background Research infrastructures are facilities or resources that have proven fundamental for supporting scientific research and innovation. However, they are also known to be very expensive in their establishment, operation and maintenance. As by far the biggest share of these costs is always borne by public funders, there is a strong interest and indeed a necessity to develop alternative business models for such infrastructures that allow them to function in a more sustainable manner that is less dependent on public financing. Methods In this article, we describe a feasibility study we have undertaken to develop a potentially sustainable business model for a vaccine research and development (R&D) infrastructure. The model we have developed integrates two different types of business models that would provide the infrastructure with two different types of revenue streams which would facilitate its establishment and would be a measure of risk reduction. For the business model we are proposing, we have undertaken an ex ante impact assessment that estimates the expected impact for a vaccine R&D infrastructure based on the proposed models along three different dimensions: health, society and economy. Results Our impact assessment demonstrates that such a vaccine R&D infrastructure could achieve a very significant socio-economic impact, and so its establishment is therefore considered worthwhile pursuing. Conclusions The business model we have developed, the impact assessment and the overall process we have followed might also be of interest to other research infrastructure initiatives in the biomedical field.
Authors: Stefan Jungbluth, William Martin, Monika Slezak, Hilde Depraetere, Carlos A. Guzman, Anton Ussi, David Morrow, Fran Van Heuverswyn, Sven Arnouts, Manuel J. T. Carrondo, Ole Olesen, Tom H.M. Ottenhoff, H. M. Dockrell, Mei Mei Ho, Alexandre Dobly, Dennis Christensen, Joaquim Segalés, Fabrice Laurent, Frédéric Lantier, Norbert Stockhofe-Zurwieden, Francesca Morelli, Jan A.M. Langermans, Frank A.W. Verreck, Roger Le Grand, Arjen Sloots, Donata Medaglini, Maria Lawrenz, Nicolas Collin
Institutions: European Vaccine Initiative, Helmholtz Centre for Infection Research, European Infrastructure for Translational Medicine, Ghent University, Instituto de Biologia Experimental e Tecnológica, Leiden University Medical Center, London School of Hygiene & Tropical Medicine, Medicines and Healthcare products Regulatory Agency, Sciensano (Belgium), Statens Serum Institut, Centre de Recerca en Sanitat Animal, Animal Health Research Center, Université de Tours, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Infectiologie et santé publique, Wageningen University & Research, Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine, Biomedical Primate Research Centre, Inserm, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, CEA Paris-Saclay - Etablissement de Saclay, CEA Paris-Saclay - Etablissement de Fontenay-aux-roses, Infectious Disease Models and Innovative Therapies, Intravacc (Netherlands), University of Siena, Vaccine Formulation Institute
Language: English
Subfield: Information Systems and Management
Field: Decision Sciences
Domain: Social Sciences
Open Access status: gold
OpenAlex ID: W4416631895
Cites:
Cited by:
Related to: